Welcome to our dedicated page for Applied Therapeutics SEC filings (Ticker: APLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial readouts, FDA meetings, and frequent capital raises make Applied Therapeutics鈥� SEC filings both crucial and complex. Skimming a 250-page 10-K to learn whether govorestat met its Phase 3 endpoints or how long cash reserves will last can cost hours.
Stock Titan solves that problem. Our AI-powered summaries break down each Applied Therapeutics annual report 10-K simplified section by section鈥擱&D expense trends, orphan-drug milestones, and going-concern language鈥攕o you understand the story, not just the jargon. AG真人官方-time alerts push every Applied Therapeutics 8-K material events explained notice to your dashboard, while insider trading Form 4 transactions are streamed the moment executives buy or sell shares.
Need specific answers? Type a natural question鈥斺淗ow much dilution did APLT鈥檚 last S-3 cause?鈥濃攁nd get instant context drawn from the filing text. Our coverage spans:
- 10-Q updates for quarter-over-quarter burn analysis (Applied Therapeutics quarterly earnings report 10-Q filing)
- Form 4 insider transactions real-time to track executive stock moves (Applied Therapeutics executive stock transactions Form 4)
- DEF 14A proxy statement executive compensation details
- 8-K clinical data releases and financing announcements
Whether you鈥檙e modeling cash runway, monitoring Applied Therapeutics insider trading Form 4 transactions, or seeking a plain-English explanation of pipeline risks, our platform keeps you ahead with complete, continuously updated SEC coverage and concise AI insights.
Applied Therapeutics, Inc. disclosed that Nasdaq notified the company its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days, triggering an initial compliance period. Nasdaq has now granted an additional 180-calendar-day extension to regain compliance with the $1.00 bid-price requirement, extending the deadline to February 2, 2026. In connection with the extension, the company鈥檚 listing will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025. The Extension Notice does not immediately affect the listing, and the company says it will monitor the bid price and consider available options, including a reverse stock split, to attempt to regain compliance. If the bid price reaches at least $1.00 for 10 consecutive business days before the deadline, Nasdaq will confirm compliance; otherwise Nasdaq may initiate delisting procedures and the company could appeal.
Applied Therapeutics, Inc. reported unaudited Q2 2025 financials showing a sharp decline in liquidity and continued operating losses. Cash and cash equivalents totaled $30.4 million at June 30, 2025, down from $79.4 million at December 31, 2024, while total assets fell to $37.3 million from $86.7 million. The company recorded a net loss of $21.3 million for the quarter and $43.2 million for the six months ended June 30, 2025, driven by R&D and G&A expenses. Operating cash used was $49.0 million for the six months.
The company disclosed material events: an FDA Complete Response Letter and Warning Letter related to the govorestat (AT-007) NDA for Classic Galactosemia, ongoing securities and derivative litigation, and management concluded that substantial doubt exists about its ability to continue as a going concern within one year. Offsetting commercial arrangements include a license to Advanz Pharma with an upfront EUR 10.0 million payment and potential future milestones and royalties, and a subsequent July 31, 2025 out-license of AT-001 to Biossil with a $1.0 million upfront payment.